Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro

European Journal of Pharmacology

Volumn 660, Issue 2-3, 2011, Pages 298-304

  Weiss, Johanna ^a   Herzog, Melanie ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ambrisentan; Bosentan; Drug metabolising enzyme; Drug transporter; Induction; Pulmonary arterial hypertension

Indexed keywords

ABC TRANSPORTER; AMBRISENTAN; BOSENTAN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; PREGNANE X RECEPTOR; PROTEIN ABCB11; PROTEIN ABCC2; PROTEIN SLCO2B1; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL STRAIN HUH 7; CELL STRAIN LS180; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYMES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METABOLIC DETOXICATION, DRUG; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHENYLPROPIONATES; PYRIDAZINES; RECEPTOR, ENDOTHELIN A; SULFONAMIDES;

EID: 79956096972     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.003     Document Type: Article

References (43)

1. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D.J., Suchy, F.J., 2001. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857-28865.
2. Binet, I., Wallnöfer, A., Weber, C., Jones, R., Thiel, G., 2000. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 57, 224-231. (Pubitemid 30227769)
3. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P., Loor, F., 1991. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51, 4226-4233.
4. Burgess, G., Hoogkamer, H., Collings, L., Dingemanse, J., 2008. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol. 64, 43-50.
5. Casserly, B., Klinger, J.R., 2009. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des. Devel. Ther. 2, 265-280.
6. Croxtall, J.D., Keam, S.J., 2008. Ambrisentan. Drugs 68, 2195-2204.
7. Dingemanse, J., van Giersbergen, P.L., 2004. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43, 1089-1115.
8. Dingemanse, J., Schaarschmidt, D., van Giersbergen, P.L., 2003. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin. Pharmacokinet. 42, 293-301.
9. Dixit, V., Hariparsad, N., Li, F., Desai, P., Thummel, K.E., Unadkat, J.D., 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35, 1853-1859.
10. Drocourt, L., Ourlin, J.C., Pascussi, J.M., Maurel, P., Vilarem, M.J., 2002. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 277, 25125-25132.
11. Fröhlich, M., Albermann, N., Sauer, A., Walter-Sack, I., Haefeli, W.E., Weiss, J., 2004. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem. Pharmacol. 68, 2409-2416.
12. Galiè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., Simonneau, G., 2005. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148-2157.
13. Galiè, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J.S., Gomez-Sanchez, M.A., Jondeau, G., Klepetko, W., Opitz, C., Peacock, A., Rubin, L., Zellweger, M., Simonneau, G., 2009a. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 34, 1219-1263.
14. Galiè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., Safdar, Z., Shapiro, S., White, R.J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R.J., on behalf of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group, 2009b. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894-2903.
15. Gilead Sciences I, 2007. Food and Drug Administration [Clinical Pharmacology & Biopharmaceutics Review (part 1)] for Original New Drug Application 22-081. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/ 022081s000TOC.cfm.
16. Gupta, A., Mugundu, G.M., Desai, P.B., Thummel, K.E., Unadkat, J.D., 2008. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab. Dispos. 36, 1172-1180.
17. Gurley, B.J., Swain, A., Williams, D.K., Barone, G., Battu, S.K., 2008. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. Food Res. 52, 772-779.
18. Hariparsad, N., Nallani, S.C., Sane, R.S., Buckley, D.J., Buckley, A.R., Desai, P.B., 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44, 1273-1281.
19. Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y., Fardel, O., 2006. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 34, 1756-1763.
20. König, S.K., Herzog, M., Theile, D., Zembruski, N., Haefeli, W.E., Weiss, J., 2010. Impact of drug transporters for the cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother. 65, 2319-2328.
21. Lindenmaier, H., Becker, M., Haefeli, W.E., Weiss, J., 2005. Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab. Dispos. 33, 1576-1579. (Pubitemid 41539950)
22. Mano, Y., Usui, T., Kamimura, H., 2007. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos. 28, 13-18.
23. Meyer Zu Schwabedissen, H.E., Böttcher, K., Chaudhry, A., Kroemer, H.K., Schuetz, E.G., Kim, R.B., 2010. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 52, 1797-1807.
24. Moore, J.T., Kliewer, S.A., 2000. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153, 1-10.
25. Ohno, S., Nakajin, S., 2009. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 37, 32-40.
26. Peters, T., Lindenmaier, H., Haefeli, W.E., Weiss, J., 2006. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 372, 291-299.
27. Plasschaert, S.L., de Bont, E.S., Boezen, M., vander Kolk,, D.M., Daenen, S.M., Faber, K.N., Kamps, W.A., de Vries, E.G., Vellenga, E., 2005. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin. Cancer Res. 11, 8661-8668.
28. Richards, D.B., Spence, R., Mandagere, A., Henderson, L.S., Magee, M.H., 2011. Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers. J. Clin. Pharmacol. 51, 102-106.
29. Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., Landzberg, M., Simonneau, G., 2002. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903.
30. Spence, R., Mandagere, A., Dufton, C., Venitz, J., 2008. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J. Clin. Pharmacol. 48, 1451-1459.
31. Spence, R., Mandagere, A., Harrison, B., Dufton, C., Boinpally, R., 2009. No clinically relevant pharmacokientic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J. Pharm. Sci. 98, 4962-4974.
32. Storch, C.H., Theile, D., Lindenmaier, H., Haefeli, W.E., Weiss, J., 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73, 1573-1581.
33. Svecova, L., Vrzal, R., Burysek, L., Anzenbacherova, E., Cerveny, L., Grim, J., Trejtnar, F., Kunes, J., Pour, M., Staud, F., Anzenbacher, P., Dvorak, Z., Pavek, P., 2008. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab. Dispos. 36, 339-348.
34. van Giersbergen, P.L., Gnerre, C., Treiber, A., Dingemanse, J., Meyer, U.A., 2002. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur. J. Pharmacol. 450, 115-121.
35. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F., 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 RESEARCH0034.
36. Weber, C., Banken, L., Birnboeck, H., Schulz, R., 1999a. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. 39, 847-854.
37. Weber, C., Banken, L., Birnboeck, H., Nave, S., Schulz, R., 1999b. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br. J. Clin. Pharmacol. 47, 701-706.
38. Weiss, J., Haefeli, W.E., 2006. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab. Dispos. 34, 203-207.
39. Weiss, J., Dormann, S.M., Martin-Facklam, M., Kerpen, C.J., Ketabi-Kiyanvash, N., Haefeli, W.E., 2003. Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther. 305, 197-204.
40. Weiss, J., Herzog, M., König, S., Storch, C.H., Ketabi-Kiyanvash, N., Haefeli, W.E., 2009a. Induction of multiple drug transporters by efavirenz. J. Pharmacol. Sci. 109, 242-250.
41. Weiss, J., Sauer, A., Herzog, M., Böger, R.H., Haefeli, W.E., Benndorf, R.A., 2009b. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 84, 264-270.
42. Wrishko, R.E., Dingemanse, J., Yu, A., Darstein, C., Phillips, D.L., Mitchell, M.I., 2008. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J. Clin. Pharmacol. 48, 610-618.
43. Zhang, L., Zhang, Y.D., Strong, J.M., Reynolds, K.S., Huang, S.M., 2008. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38, 709-724.